Patents Examined by Umamaheswari Ramachandran
  • Treatment of circadian rhythm disorders
    Patent number: 11090285
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 17, 2021
    Assignee: VANDA PHARMACEUTICALS INC
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 11091484
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Composition and apparatus for treatment of chemotherapy induced alopecia
    Patent number: 11077088
    Abstract: A composition for use in cooling therapy and treatment of chemically induced alopecia (CIA), said composition containing a reactive oxygen species (ROS) inhibitor.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: August 3, 2021
    Assignee: Paxman Coolers Ltd
    Inventors: Nikolaos Georgopoulos, Andrew Collett, Richard Paxman
  • Compositions and methods for the treatment of Zellweger spectrum disorder
    Patent number: 11065247
    Abstract: Provided herein are methods of treating Zellweger spectrum disorder (ZSD) in a subject in need thereof or improving peroxisome assembly in a cell in need thereof comprising administering to the subject a therapeutically effective amount of Compounds of Formula I or II.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 20, 2021
    Inventors: Joseph Hacia, Nancy E. Braverman, Patricia Dranchak, James Inglese
  • Combination therapies with disulfiram
    Patent number: 11065214
    Abstract: Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: July 20, 2021
    Assignee: Spring Discovery, Inc.
    Inventors: Rachel Jacobson, Wendy Cousin, An Nguyen, Tempest Plott, William Van Trump, Dat Nguyen, Daniel Chen, Jarred Heinrich, Ben Komalo, Lauren Nicolaisen, Christian Elabd
  • In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
    Patent number: 11058664
    Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: July 13, 2021
    Assignees: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
  • Therapeutic targeting of SET1B/compass pathway for treating cancers
    Patent number: 11059878
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • Treatment and prevention of bone and joint disorders
    Patent number: 11039636
    Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and/or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Summit Innovation Labs, LLC
    Inventors: Ghebre Egziabher Tzeghai, Haile Mehansho, Satyanarayana Majeti
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 11040998
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: June 22, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • STAT3 inhibitors
    Patent number: 11026905
    Abstract: Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 8, 2021
    Assignees: Tvardi Therapeutics, Inc., Baylor College of Medicine
    Inventors: Sofia De Achaval, David John Tweardy
  • Treatment for non-alcoholic fatty liver diseases
    Patent number: 11026916
    Abstract: Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 8, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Szabolcs Peter, Joseph Schwager
  • Non-pharmaceutical bactericidal composition against
    Patent number: 11013706
    Abstract: The present invention provides a non-pharmaceutical bactericidal composition against a Helicobacter pylori, including a first daily edible component and a second daily edible component.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 25, 2021
    Assignee: ECO-GEO BIO-TECHNOLOGY COMPANY LIMITED.
    Inventors: Ta-Lu Shen, Fu-An Chen
  • Treatment and prevention of joint disorders
    Patent number: 11007171
    Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoarthritis and rheumatoid arthritis and for promoting overall joint health. This is accomplished by totally addressing the key multiple biochemical processes and mechanisms that lead to such disorders. The invention includes compositions comprising a combination of natural agents that safely and effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that increase the risk for or lead to the development and/or progression of OA and RA.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 18, 2021
    Assignee: Summit Innovation Labs, LLC
    Inventors: Haile Mehansho, Satyanarayana Majeti, Ghebre Egziabher Tzeghai
  • Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
    Patent number: 11007173
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 18, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Jonathan Rowe
  • Food supplement and composition comprising choline butyrate salt and/or butyrylcholine
    Patent number: 11007159
    Abstract: The present Invention relates to the use of choline butyrate or butyrylcholine in food and in particular in the treatment of Intestinal disorders and in the stimulation of the brain development. Furthermore, the invention provides for a food supplement and a pharmaceutical composition comprising choline butyrate or butyrylcholine, The invention also relates to an animal feed comprising choline butyrate or butyrylcholine or said food supplement.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 18, 2021
    Assignee: ABERGAVENNY NV
    Inventor: Marc Vanden Avenne
  • Amino-aryl-benzamide compounds and methods of use thereof
    Patent number: 11000491
    Abstract: A method for the treatment and/or reduction of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is disclosed. The method uses active amino-aryl-benzamide compounds and methods for the preparation thereof.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 11, 2021
    Assignee: Hepanova, Inc.
    Inventors: Ke Li, Belle Xiaohong Wang, Yongmei Li, Qiong Li
  • Substituted hydroxystilbenes as AhR and Nrf2 modulators and their therapeutic applications
    Patent number: 11000485
    Abstract: It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: December 16, 2018
    Date of Patent: May 11, 2021
    Assignee: Resolvex Pharmaceuticals Inc.
    Inventors: Liren Tang, Michael Patrick Allen Lyle, Youwen Zhou
  • De-epoxidized epothilone derivative preparation, preparation of same and use thereof in the treatment of tumor
    Patent number: 10980782
    Abstract: The present application discloses a pharmaceutical preparation comprising a de-epoxidized epothilone derivative, and especially relates to a preparation formulation of a compound with reduced allergens and toxicity; and also relates to the use thereof in the treatment of tumours, especially the use thereof in the treatment of solid tumours that are resistant to and fail to respond to other conventional chemotherapeutic agents, as well as the use thereof in the treatment of cancers alone or in combination with other tumour drugs or auxiliary drugs.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: April 20, 2021
    Assignees: BEIJING BIOSTAR TECHNOLOGIES, LTD., CHENGDU BIOSTAR PHARMACEUTICALS, LTD.
    Inventors: Li Tang, Rongguo Qiu
  • Oral liquid compositions including valsartan
    Patent number: 10973802
    Abstract: An aspect of the present disclosure is directed to an oral liquid composition comprising valsartan with enhanced solubility and stability. Other aspects are directed to methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 13, 2021
    Assignee: ECI PHARMACEUTICALS, LLC
    Inventor: Greg Thomas
  • [2.2.2] bicyclic derivatives and methods of use
    Patent number: 10966944
    Abstract: Administration of a salt of bicyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 6, 2021
    Inventor: Susanna A. Saakian